BIOGEN INC (BIIB)

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 8,725 full-time employees. The firm is focused on discovering, developing and delivering therapies for people living with serious and complex diseases worldwide. The company has a portfolio of medicines to treat multiple sclerosis, spinal muscular atrophy (SMA) and Alzheimer's disease. The company is focused on advancing its pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; FUMADERM for the treatment of severe plaque psoriasis, and SKYCLARYS (omaveloxolone). The company is also advancing its mid-to-late stage programs, including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD); BIIB080 for Alzheimer's disease; tofersen for amyotrophic lateral sclerosis (ALS), and both litifilimab and dapirolizumab pegol for certain forms of lupus.

Company Info

BIOGEN INC

225 Binney Street

Cambridge MASSACHUSETTS 02142

P: 17814642000

CEO: Michel Vounatsos

Employees: 8725

Website: https://www.biogen.com/